The emerging role of cannabinoid neuromodulators in symptom management.

Article Details

Citation

Davis M, Maida V, Daeninck P, Pergolizzi J

The emerging role of cannabinoid neuromodulators in symptom management.

Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1.

PubMed ID
17139494 [ View in PubMed
]
Abstract

INTRODUCTION: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. DISCUSSION: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. SUMMARY: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
DronabinolCannabinoid receptor 2ProteinHumans
Yes
Agonist
Details
NabiloneCannabinoid receptor 1ProteinHumans
Yes
Partial agonist
Details
NabiloneCannabinoid receptor 2ProteinHumans
Yes
Partial agonist
Details